메뉴 건너뛰기




Volumn 136, Issue 10, 2012, Pages 1201-1204

Treatment of ALK-positive non-small cell lung cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

EID: 84868312005     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0246-RA     Document Type: Conference Paper
Times cited : (30)

References (30)
  • 1
    • 79251490374 scopus 로고    scopus 로고
    • New driver mutations in non-small-cell lung cancer
    • Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
    • (2011) Lancet Oncol , vol.12 , Issue.2 , pp. 175-180
    • Pao, W.1    Girard, N.2
  • 2
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
    • (2007) Nature , vol.448 , Issue.7153 , pp. 561-566
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3
  • 3
    • 36849065315 scopus 로고    scopus 로고
    • Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
    • Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190- 1203.
    • (2007) Cell , vol.131 , Issue.6 , pp. 1190-1203
    • Rikova, K.1    Guo, A.2    Zeng, Q.3
  • 4
    • 84856877692 scopus 로고    scopus 로고
    • The potential for crizotinib in non-small cell lung cancer: A perspective review
    • Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011;3(6):279-291.
    • (2011) Ther Adv Med Oncol , vol.3 , Issue.6 , pp. 279-291
    • Bang, Y.J.1
  • 5
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693- 1703.
    • (2010) N Engl J Med , vol.363 , Issue.18 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3
  • 6
    • 70349336416 scopus 로고    scopus 로고
    • Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.
    • (2009) J Clin Oncol , vol.27 , Issue.26 , pp. 4247-4253
    • Shaw, A.T.1    Yeap, B.Y.2    Mino-Kenudson, M.3
  • 7
    • 69349083935 scopus 로고    scopus 로고
    • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
    • Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216-5223.
    • (2009) Clin Cancer Res , vol.15 , Issue.16 , pp. 5216-5223
    • Rodig, S.J.1    Mino-Kenudson, M.2    Dacic, S.3
  • 8
    • 77649091118 scopus 로고    scopus 로고
    • A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
    • Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
    • (2010) Clin Cancer Res , vol.16 , Issue.5 , pp. 1561-1571
    • Mino-Kenudson, M.1    Chirieac, L.R.2    Law, K.3
  • 10
    • 77958072139 scopus 로고    scopus 로고
    • The tissue is the issue: Personalized medicine for non-small cell lung cancer
    • Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010; 16(20):4909-4911.
    • (2010) Clin Cancer Res , vol.16 , Issue.20 , pp. 4909-4911
    • Hirsch, F.R.1    Wynes, M.W.2    Gandara, D.R.3    Bunn Jr., P.A.4
  • 11
    • 37549059613 scopus 로고    scopus 로고
    • Cytoreductive antitumor activity of PF-2341066, A novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
    • Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007; 6(12, pt 1):3314-3322.
    • (2007) Mol Cancer Ther , vol.6 , Issue.12 PART 1 , pp. 3314-3322
    • Christensen, J.G.1    Zou, H.Y.2    Arango, M.E.3
  • 12
    • 34249324494 scopus 로고    scopus 로고
    • An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
    • Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408-4417.
    • (2007) Cancer Res , vol.67 , Issue.9 , pp. 4408-4417
    • Zou, H.Y.1    Li, Q.2    Lee, J.H.3
  • 13
    • 77955174967 scopus 로고    scopus 로고
    • Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]
    • Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract 3]. J Clin Oncol. 2010;28(suppl):18s.
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL.
    • Bang, Y.1    Kwak, E.L.2    Shaw, A.T.3
  • 14
    • 80052492099 scopus 로고    scopus 로고
    • Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]
    • Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) [abstract 2501]. J Clin Oncol. 2011;29(suppl):165s.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Camidge, D.R.1    Bang, Y.2    Kwak, E.L.3
  • 15
    • 80051780280 scopus 로고    scopus 로고
    • Initial phase 2 results with crizotinib inadvanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]
    • Crinò L, Kim D-W, Riely G, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 7514]. J Clin Oncol. 2011;29(suppl):479s.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Crinò, L.1    Kim, D.-W.2    Riely, G.3
  • 16
    • 84870894199 scopus 로고    scopus 로고
    • Accessed October, 7, 2011
    • Xalkori prescribing information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202570s000lbl.pdf. Accessed October 7, 2011
    • Xalkori prescribing information
  • 17
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
    • (2004) J Clin Oncol , vol.22 , Issue.9 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 18
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
    • (2005) N Engl J Med , vol.353 , Issue.2 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues, P.J.2    Ciuleanu, T.3
  • 19
    • 84864432794 scopus 로고    scopus 로고
    • Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) Gene rearrangement, ALK Signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization- positive nonsmall cell lung Cancer
    • [published online ahead of print January], doi:10.1002/cncr. 27411
    • Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer [published online ahead of print January 26, 2012]. Cancer. doi:10.1002/cncr. 27411.
    • Cancer , vol.26 , pp. 2012
    • Camidge, D.R.1    Theodoro, M.2    Maxson, D.A.3
  • 20
    • 79951994379 scopus 로고    scopus 로고
    • Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies
    • Ou SHI, Salgia R, Clark J. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. J Thorac Oncol. 2010;5(suppl. 5):S382.
    • (2010) J Thorac Oncol , vol.5 , Issue.SUPPL. 5
    • Ou, S.H.I.1    Salgia, R.2    Clark, J.3
  • 21
    • 80054728915 scopus 로고    scopus 로고
    • Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 1618]
    • Riely G, Kim D-W, Crinò L, et al. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced non-small cell lung cancer (NSCLC): PROFILE 1005 [abstract 1618]. J Thorac Oncol. 2011;6(suppl 2):411s.
    • (2011) J Thorac Oncol , vol.6 , Issue.SUPPL.. 2
    • Riely, G.1    Kim, D.-W.2    Crinò, L.3
  • 22
    • 80053386829 scopus 로고    scopus 로고
    • Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: A retrospective analysis
    • Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;11:1004-1012.
    • (2011) Lancet Oncol , vol.11 , pp. 1004-1012
    • Shaw, A.T.1    Yeap, B.Y.2    Solomon, B.J.3
  • 23
    • 84859507778 scopus 로고    scopus 로고
    • Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer
    • Poster Presented At, Stockholm, Sweden. Abstract 3030., September
    • Solomon B, Chiappori A, Lamb A, et al. Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer. Poster presented at: European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 3030.
    • (2011) European Multidisciplinary Cancer Congress , pp. 23-27
    • Solomon, B.1    Chiappori, A.2    Lamb, A.3
  • 24
    • 84859507780 scopus 로고    scopus 로고
    • PROFILE 1005: Preliminary patient-reported outcomes (PROs), from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC)
    • Oral presentation at, Amsterdam, The Netherlands., July
    • Blackhall FH, Petersen JA, Wilner K, et al. PROFILE 1005: preliminary patient-reported outcomes (PROs) from an ongoing phase 2 study of crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive advanced nonsmall cell lung cancer (NSCLC). Oral presentation at: 14th World Conference on Lung Cancer (WCLC); July 3-7, 2011; Amsterdam, The Netherlands.
    • (2011) 14th World Conference on Lung Cancer (WCLC) , pp. 3-7
    • Blackhall, F.H.1    Petersen, J.A.2    Wilner, K.3
  • 25
    • 84869451039 scopus 로고    scopus 로고
    • A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC) [abstract]
    • Kim DW, Blackhall F, Soria JC, et al. A global phase 2 study including efficacy, safety and patient-reported outcomes (PROs) with crizotinib in patients (Pts) with ALK-positive non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer. 2011;47(suppl):S617.
    • (2011) Eur J Cancer , vol.47 , Issue.SUPPL..
    • Kim, D.W.1    Blackhall, F.2    Soria, J.C.3
  • 26
    • 81355124049 scopus 로고    scopus 로고
    • Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen
    • Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78(6):999-1005.
    • (2011) Chem Biol Drug Des , vol.78 , Issue.6 , pp. 999-1005
    • Zhang, S.1    Wang, F.2    Keats, J.3
  • 27
    • 80052793410 scopus 로고    scopus 로고
    • A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
    • Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71(18):6051-6060.
    • (2011) Cancer Res , vol.71 , Issue.18 , pp. 6051-6060
    • Sasaki, T.1    Koivunen, J.2    Ogino, A.3
  • 28
    • 78049426513 scopus 로고    scopus 로고
    • EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
    • Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734-1739.
    • (2010) N Engl J Med , vol.363 , Issue.18 , pp. 1734-1739
    • Choi, Y.L.1    Soda, M.2    Yamashita, Y.3
  • 29
    • 84856999699 scopus 로고    scopus 로고
    • Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
    • Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17.
    • (2012) Sci Transl Med , vol.4 , Issue.120
    • Katayama, R.1    Shaw, A.T.2    Khan, T.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.